Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...

Ecopipam is a first-in-class investigational small-molecule therapy that selectively blocks dopamine-1 (D1) receptors. It is not an antipsychotic. This mechanism differs from currently approved ...

That first cigarette can lead to a lifetime of dependency, as well as cancer, strokes, heart attacks … Here’s why smokers crave their nicotine hit – and how they can fight back ...

Post hoc analyses of two Phase 2 trials examine the potential benefits of solengepras, a once-daily, oral, non-dopaminergic ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

The bipolar depression market is anticipated to increase during the forecast period (2026--2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), ...

Stimulant medications can make some people have a smaller appetite. If you take both a GLP⁠-1 and a stimulant, you might not feel the need to eat as much as you need to. That could cause you to lose ...

Preclinical studies in animals have already shown that GLP-1 drugs can reduce reward-seeking behavior. Early clinical work in humans has begun to hint at similar effects. A randomized trial of ...

The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

H. Lundbeck A/S (Lundbeck) today announced that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented ...

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented at the 2026 AD/PD ConferenceData evaluated safety, tolerability, pharmacokinetic ...